Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech's stock price has experienced significant volatility and a substantial decline over the past year. In February 2026, the company announced the exercise of warrants, generating approximately $8.3 million in gross proceeds, which coincided with a significant stock price decrease. The initial reports in January 2026 indicated the first unblinding of 45 treated subjects in the pivotal Phase 2B/3 MIRACLE trial for Annamycin was expected in Q1 2026, later updates in March 2026 confirmed this interim unblinding was on track for mid-2026. The average analyst price target for Moleculin Biotech saw a downward revision of 58.82% over the three months leading up to April 2, 2026. In March 2026, Moleculin reported its full-year 2025 financial results, confirming the 40% blinded CRc and a cash runway into Q3 2026, with a net loss of -$33.56 million for the full year 2025. The company has released CEO Corner segments and participated in conferences.

There is no specific information available regarding demand seasonality for Moleculin Biotech, Inc.'s products and services. Demand for its drug candidates is primarily driven by medical need, clinical trial success, regulatory approvals, and market access, rather than seasonal patterns.

Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on creating therapeutic candidates for the treatment of highly resistant tumors and viruses, operating within the Healthcare sector, specifically in the Biotechnology and Medical Research industry. Its major product candidates include Annamycin, an anthracycline in clinical stages for treating relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases; the WP1066 Portfolio, immune/transcription modulators aimed at inhibiting phosphorylated signal transducer and activator of transcription (p-STAT3) for various cancers; and the WP1122 Portfolio, designed to exploit inhibitors of glycolysis to cut off the energy supply of tumors.

Moleculin Biotech, Inc. is headquartered in Houston, Texas, United States. The company's clinical trials, particularly the pivotal Phase 2B/3 MIRACLE trial for Annamycin, are global, with patient enrollment across seven countries, and there is also a clinical trial in the EU.

Moleculin Biotech's brand reputation has been influenced by its clinical trial progress and financial activities. Positive developments, such as encouraging preliminary blinded data from the MIRACLE trial and securing a notice of allowance from the Japan Patent Office, have contributed positively. However, events like the significant stock price decline, dilution caused by warrant exercises, and the delayed timeline for definitive data readout from the MIRACLE trial have likely put pressure on its reputation among investors. The company's financial results for 2025, showing a net loss, also contribute to the overall financial perception.

Moleculin Biotech, Inc. has a mix of institutional and individual owners, with approximately 15.52% of its stock owned by institutional investors. Major institutional owners include Citadel Advisors Llc, Jane Street Group, Llc, and Vanguard Group Inc. Major individual owners (insiders) include Waldemar Priebe, Walter V. Klemp, and Donald H. Picker.